A new monoclonal antibody (CAL2) detects CALRETICULIN mutations in formalin-fixed and paraffin-embedded bone marrow biopsies

Leukemia

Volumn 30, Issue 1, 2016, Pages 131-135

  Stein, H ^a   Bob, R ^a   Durkop H ^a   Erck, C ^b   Kampfe D ^c   Kvasnicka, H M ^d   Martens, H ^b   Roth, A ^e   Streubel, A ^e  

^a Berlin Reference Center for Lymphoma and Haematopathology   (Germany)

^b SYNAPTIC SYSTEMS GMBH   (Germany)

^c Praxis für Hämatologie und Onkologie   (Germany)

^d GOETHE UNIVERSITY   (Germany)

^e HELIOS KLINIKUM EMIL VON BEHRING   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CALRETICULIN; JANUS KINASE 2; MONOCLONAL ANTIBODY; CALRETICULIN, HUMAN; FORMALDEHYDE; PARAFFIN;

ARTICLE; BONE MARROW BIOPSY; CARBOXY TERMINAL SEQUENCE; FRAMESHIFT MUTATION; GENE MUTATION; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MASTOCYTOSIS; MOUSE; MYELOPROLIFERATIVE NEOPLASM; NONHUMAN; POLYCYTHEMIA VERA; PRIORITY JOURNAL; THROMBOCYTHEMIA; AMINO ACID SEQUENCE; ANIMAL; BIOPSY; BONE MARROW; CHEMISTRY; GENETICS; HEK293 CELL LINE; IMMUNOLOGY; MOLECULAR GENETICS; MUTATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; BIOPSY; BONE MARROW; CALRETICULIN; FORMALDEHYDE; HEK293 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MOLECULAR SEQUENCE DATA; MUTATION; PARAFFIN EMBEDDING;

EID: 84953366841     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.192     Document Type: Article

References (11)

1. Antonioli E, Guglielmelli P, Pancrazzi A, Bogani C, Verrucci M, Ponziani V et al. Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia 2005; 19: 1847-1849.
2. Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005; 366: 1945-1953.
3. Wolanskyj AP, Lasho TL, Schwager SM, McClure RF, Wadleigh M, Lee SJ et al. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol 2005; 131: 208-213.
4. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds). WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. International Agency for Research on Cancer: Lyon, France, 2008.
5. Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013; 369: 2391-2405.
6. Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013; 369: 2379-2390.
7. Rumi E, Pietra D, Guglielmelli P, Bordoni R, Casetti I, Milanesi C et al. Acquired copyneutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms. Blood 2013; 121: 4388-4395.
8. Vannucchi AM, Rotunno G, Bartalucci N, Raugei G, Carrai V, Balliu M et al. CAL mut-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value. Leukemia 2014; 28: 1811-1818.
9. Bob R, Falini B, Marafioti T, Paterson JC, Pileri S, Stein H. Nodal reactive and neoplastic proliferation of monocytoid and marginal zone B cells: an immunoarchitectural and molecular study highlighting the relevance of IRTA1 and T-bet as positive markers. Histopathology 2013; 63: 482-498.
10. Cabagnols X, Defour JP, Ugo V, Ianotto JC, Mossuz P, Mondet J et al. Differentia association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution. Leukemia 2015; 29: 249-252.
11. Jones AV, Ward D, Lyon M, Leung W, Callaway A, Chase A et al. Evaluation of methods to detect CALR mutations in myeloproliferative neoplasms. Leuk Res 2015; 39: 82-87.